Résztvevőt keres itt: Olaszország3. fázis
CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
A legfontosabb adatok
- Ki végzi
- Niguarda Hospital
- Hol
- Ancona, Arezzo, Bologna, Milan, Naples, Roma, Rome, Trieste, Turin és Udine (Olaszország)Mind a 12 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 80 fő, tervezett
- Kezdés
- 2023. nov. 14.
- Várható befejezés
- 2029. aug. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Colchicine
- Placebo
- A regiszteradat frissítve
- 2026. november 13.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 34 feltétel megnézéseKevesebb
Ki vehet részt
- Males and females with Infl-CMP associated with VA (including high PVC burden), reduced LVEF, or significantly increased levels of natriuretic peptides
- Patients of 18 years or older
- Evidence of myocardial inflammation on CMRI (using 2018 Lake Louis criteria) or FDG-PET performed in the 3 months before randomization to be included in the trial OR in the last 12 months before for the registry
- Presence of any of the following characteristics and if symptoms have been present for more than 1 month:
- Mono-morphic or polymorphic PVC burden of ≥500 in 24 hours, or NSVTs (defined as >3 consecutive beats at rate > 100 beats per minute lasting <30 seconds) or evidence of sustained ventricular tachycardias (SVT)
- Reduced LVEF on echocardiogram (<50%) or on CMRI (<60%)-. Increased N-terminal pro-B-type natriuretic peptide (NT- proBNP) concentration of 1000 pg/mL or more, or a B-type natriuretic peptide (BNP) concentration of 200 pg/mL or more
- Family members of the probands with negative cardiac phenotype (FMPNCP) for myocarditis
Ki nem vehet részt
- Cardiomyopathy attributed to toxins such as alcohol and illicit drugs, or to specific causes (i.e. amyloidosis or hypertrophic cardiomyopathy)
- Previous history of cardiac surgery for instance correction of congenital heart disease or a valve repair/replacement
- Participants involved in another clinical trial, defined by the participation in a clinical trial in which an investigational drug was administered in the 30 days prior to screening, or 5 half-lives of the study drug, whichever is longer
- Cardiomyopathy attributed to toxins such as alcohol and illicit drugs, or to specific causes (i.e. amyloidosis or hypertrophic cardiomyopathy)
- Previous history of cardiac surgery for instance correction of congenital heart disease or a valve repair/replacement
- Participants involved in another clinical trial, defined by the participation in a clinical trial in which an investigational drug was administered in the 30 days prior to screening, or 5 half-lives of the study drug, whichever is longer
- Advance heart failure (NYHA III or need for inotropes including levosimendan), or recurrent VA despite previous catheter ablation,
- Patients already on chronic immunosuppressive therapies (including colchicine) or in whom immunosuppressive therapy is deemed necessary
- Proven history of myocardial infarction with evidence of ischemic scar on echocardiogram or CMRI,
- Significant flow-limiting coronary artery disease (stenosis above 50%) on invasive coronary angiography or computed tomography (CT) coronary angiography,
- Known systemic autoimmune disorder (the exception will be for patients with systemic autoimmune disease or isolated cardiac sarcoidosis with a family history of cardiomyopathy, myocarditis, or arrhythmias, where overlap between an autoimmune event and a genetic background can occur). These patients will undergo genetic tests. Patients with autoimmune systemic disorders and isolated cardiac sarcoidosis with positive genetic tests for MCVG will be included in the registry
- Known chronic infective disease, such as HIV infection or tuberculosis
- Any other significant disease or disorder which (expected life expectancy <12 months), in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial or the participant's ability to participate in the trial
- Proven history of myocardial infarction with evidence of ischemic scar on echocardiogram or CMRI,
- Significant flow-limiting coronary artery disease (stenosis above 50%) on invasive coronary angiography or computed tomography (CT) coronary angiography,
- Known systemic autoimmune disorder (the exception will be for patients with systemic autoimmune disease or isolated cardiac sarcoidosis with a family history of cardiomyopathy, myocarditis, or arrhythmias, where overlap between an autoimmune event and a genetic background can occur). These patients will undergo genetic tests. Patients with autoimmune systemic disorders and isolated cardiac sarcoidosis with positive genetic tests for MCVG will be included in the registry
- Known chronic infective disease, such as HIV infection or tuberculosis
- Any other significant disease or disorder which (expected life expectancy <12 months), in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial or the participant's ability to participate in the trial
- Current symptomatic atrial arrhythmias (including persistent atrial fibrillation) associated with LV dysfunction,
- Known systemic autoimmune disorder or other conditions at the time of randomization where immunosuppression is assumed useful (i.e. cardiac sarcoidosis),
- Contraindication to colchicine, including allergies to this medication and its excipients (i.e., lactose and sucrose),
- Severe gastrointestinal insufficiency (for instance, malabsorption syndrome, severe chronic diarrhea)
- Impaired renal function (eGFR<30 ml/min/1.73m2),
- Known history of hepatic cirrhosis or transaminase levels at baseline > x3-fold the URL
- Patients with peripheral eosinophilia (eosinophil count >10% of the leukocytes) or known hypereosinophilic syndrome at the time of randomization
- Women with childbearing potential (this exclusion criterion is due to insufficient human information regarding the embryofoetal risk with colchicine)
- Women during breastfeeding
Helyszínek itt: Olaszország
- Università Politecnica delle Marche e AOU Ospedali Riuniti Umberto I°-Lancisi-Salesi , AnconaAncona, OlaszországContact: Michela Casella, MDRésztvevőt keres
- ASL8 Arezzo San Donato HospitalArezzo, OlaszországContact: Michele Ciabatti, MDRésztvevőt keres
- Policlinico S. Orsola MalpighiBologna, OlaszországContact: Luciano Potena, MDRésztvevőt keres
- ASST Grande Ospedale Metropolitano NiguardaMilan, OlaszországContact: Enrico Ammirati, MD, PhDRésztvevőt keres
- Centro Cardiologico MonzinoMilan, OlaszországContact: Gianluca Pontone, MDRésztvevőt keres
- IRCCS Ospedale San RaffaeleMilan, OlaszországContact: Giovanni Peretto, MDRésztvevőt keres
- Università degli studi della Campania L.Vanvitelli e Azienda Ospedaliera Specialistica dei Colli - Ospedale MonaldiNaples, OlaszországContact: Francesco Loffredo, MDRésztvevőt keres
- Ospedale S.Spirito di SassiaRoma, OlaszországContact: Chiara Lanzillo, MD, PhDRésztvevőt keres
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome, OlaszországContact: Maria Lucia Narducci, MDRésztvevőt keres
- Azienda Sanitaria Universitaria Integrata Giuliano Isontina, TriesteTrieste, OlaszországContact: Marco Merlo, MDRésztvevőt keres
- Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di TorinoTurin, OlaszországContact: Gaetano De Ferrari, MDRésztvevőt keres
- Presidio Ospedaliero Universitario Santa Maria della MisericordiaUdine, OlaszországContact: Massimo Imazio, MDRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
Two-parallel groups randomized, single-blinded, multi-center phase III controlled trial in patients with chronic inflammatory cardiomyopathy to assess the efficacy of colchicine and associated prospective registry to assess the prognostic value of positive genetic testing in this population.
A vizsgálat 2 csoportja
- ColchicineA vizsgált kezelés
Patients treated with colchicine 0.5-1 mg (1 mg if tolerated) for 6 months.
- PlaceboPlacebo, összehasonlításként
Patients treated with placebo tablets.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Single-blinded Randomized Investigator-initiated Controlled Trial to Assess the Efficacy of Colchicine to Treat Patients With Cardiomyopathy With Myocarditis (Chronic Inflammatory Cardiomyopathy)
- Publikációk
- A regiszteradat frissítve
- 2026. november 13.